Clinical Trial

PRO-232 in Patients Subjected to Cataract Surgery

Study acronym: PRO-232
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 26, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The main objective of this study is to evaluate the efficacy and safety of the PRO-232 formulation manufactured by Laboratorios Sophia S.A. de C.V. on the ocular surface of postoperative cataract patients versus a concomitant administration of ophthalmic moxifloxacin and dexamethasone.
Trial Details
NCT Number NCT07305987
Lead Sponsor Laboratorios Sophia S.A de C.V.
Conditions Cataract Extraction
Enrollment 134 participants
Start Date 2025-10-27
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-26